 |
Insmed Appoints Will Lewis as President and Chief Executive Officer
Sep 11, 2012
|
13.4 KB |
|
| |
MONMOUTH JUNCTION, N.J., Sept. 11, 2012 /PRNewswire/ -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, today announced the appointment of Will Lewis as President and Chief Executive Officer, effective immediately. Mr. Lewis...
|
|
Insmed to Present at Stifel Nicolaus 2012 Healthcare Conference
Aug 30, 2012
|
10.2 KB |
|
| |
MONMOUTH JUNCTION, N.J., Aug. 30, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today announced that Timothy Whitten, President and Chief Executive Officer, will be presenting a corporate overvie...
|
|
Insmed to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference
Aug 14, 2012
|
10.3 KB |
|
| |
MONMOUTH JUNCTION, N.J., Aug. 14, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today announced that Timothy Whitten, President and Chief Executive Officer, will be presenting a corporate overvie...
|
|
Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012
Aug 7, 2012
|
27.2 KB |
|
| |
MONMOUTH JUNCTION, N.J., Aug. 7, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today reported results for the second quarter and six-months ended June 30, 2012.
Key Recent Highlights:
...
|
|
Pharmaceutical Industry Veteran Al Altomari Elected To Insmed's Board Of Directors
Aug 6, 2012
|
12.8 KB |
|
| |
MONMOUTH JUNCTION, N.J., Aug. 6, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced the election of Al Altomari to its Board of Directors, effective immediately. Insmed's Board of Directors now consists of seven members...
|
|
Insmed Receives Second Composition Of Matter Patent For ARIKACE®
Aug 2, 2012
|
11.5 KB |
|
| |
MONMOUTH JUNCTION, N.J., Aug. 2, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the U.S. Patent and Trademark Office has issued a new composition of matter patent for ARIKACE® (liposomal amikacin for inhala...
|
|
Insmed Announces Planned Departure Of Chief Financial Officer
Jul 30, 2012
|
9.3 KB |
|
| |
MONMOUTH JUNCTION, N.J., July 30, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the Company's Executive Vice President & Chief Financial Officer, Kevin Tully, will be leaving the Company when his current contra...
|
|
Insmed to Host 2012 Second Quarter Earnings Conference Call
Jul 24, 2012
|
11.3 KB |
|
| |
MONMOUTH JUNCTION, N.J., July 24, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, will host a conference call on Tuesday, August 7th, 2012, at 8:30 AM ET, to discuss its financial results for the second quarter of 2012. Insmed inten...
|
|
Insmed To Present At JMP Securities 7th Annual Healthcare Conference
Jul 10, 2012
|
10.3 KB |
|
| |
MONMOUTH JUNCTION, N.J., July 10, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that Renu Gupta, M.D., Executive Vice President of Development and Chief Medical Officer, will be presenting a corporate overview at th...
|
|
Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
Jul 2, 2012
|
12.6 KB |
|
| |
MONMOUTH JUNCTION, N.J., July 2, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that it has entered into a loan agreement with Hercules Technology Growth Capital, Inc. (NYSE: HTGC), a leader in customized debt financ...
|
|
Insmed Announces First Patient Dosed in TARGET-NTM Phase 2 Clinical Trial of ARIKACE® in Patients with Non-Tuberculous Mycobacteria (NTM) Lung Disease
Jun 27, 2012
|
11.7 KB |
|
| |
MONMOUTH JUNCTION, N.J., June 27, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the first patient has been dosed in the Company's U.S. phase 2 clinical study of ARIKACE® (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease entitled ...
|
|
Insmed Provides Corporate Update
May 30, 2012
|
17.9 KB |
|
| |
MONMOUTH JUNCTION, N.J., May 30, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today provided a corporate update, including the Company's current strategic development priorities for ARIKACE® (liposomal amikacin for inhalation).
"Insmed has determined that its current resources will be applie...
|
|
Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
May 23, 2012
|
15.3 KB |
|
| |
MONMOUTH JUNCTION, N.J., May 23, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it has begun screening patients for its U.S. phase 2 clinical trial, Treatment with ARIKACE to Realize Greater Efficacy Trial (TARGET-NTM), of ARIKACE® (liposomal amikacin for inhalation) in patients wi...
|
|
Insmed Appoints Donald J. Hayden, Jr. as Executive Chairman
May 16, 2012
|
13.0 KB |
|
| |
MONMOUTH JUNCTION, N.J., May 16, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced the appointments of Donald J. Hayden, Jr. as Executive Chairman of the Company's Board of Directors, and Randall Whitcomb, M.D. as the Lead Independent Director, effective immediately. Mr. Hayden has served as C...
|
|
Insmed Announces First Quarter 2012 Financial Results
May 8, 2012
|
24.0 KB |
|
| |
MONMOUTH JUNCTION, N.J., May 8, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, today reported results for the first quarter ended March 31, 2012.
Key Recent Highlights:
U.S. Food and Drug Administration (FDA) lifted clinical hold on ARIKACE® (liposomal amikacin for inhalation) in Cystic ...
|
|
Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
May 7, 2012
|
11.6 KB |
|
| |
MONMOUTH JUNCTION, N.J., May 7, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on ARIKACE® (liposomal amikacin for inhalation) in Cystic Fibrosis (CF) patients with Pseudomonas lung infection...
|
|
Insmed to Host 2012 First Quarter Earnings Conference Call
Apr 24, 2012
|
10.4 KB |
|
| |
MONMOUTH JUNCTION, N.J., April 24, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, May 8th, 2012, at 8:30 AM ET, to discuss its financial results for the first quarter of 2012. Insmed intends to issue its quarterly financial results press release before the market ope...
|
|
Insmed Announces First Patient Dosed in Pivotal European Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections
Apr 16, 2012
|
13.2 KB |
|
| |
MONMOUTH JUNCTION, N.J., April 16, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced the initiation of the Company's CLinical Evaluation of ARIKACE phase 3 study (CLEAR-108) of ARIKACE® (liposomal amikacin for inhalation) in Europe for Cystic Fibrosis (CF) patients with Pseudomonas aerugin...
|
|
Insmed Announces Fourth Quarter and Full-Year 2011 Financial Results
Mar 13, 2012
|
28.0 KB |
|
| |
MONMOUTH JUNCTION, N.J., March 13, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported results for the fourth quarter and fiscal year ended December 31, 2011.
Key Recent Highlights:
Clinical hold lifted by U.S. Food and Drug Administration (FDA) for ARIKACE® (liposomal amikacin for inha...
|
|
Insmed to Host Fourth Quarter and 2011 Year-End Earnings Conference Call
Feb 28, 2012
|
10.6 KB |
|
| |
MONMOUTH JUNCTION, N.J., Feb. 28, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, March 13th, 2012, at 8:30 AM ET, to discuss its financial results for the fourth quarter and year-end 2011. Insmed intends to issue its quarterly and year-end financial results press rel...
|
|
|
